HCW Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	0.56	2.59	0	4.1	0
Revenue Growth (YoY)	-78.33%	-	-	-	-
Gross Profit	0.56	2.59	0	4.1	0
Selling, General & Admin	13.35	8.33	5.19	2.67	1.97
Research & Development	7.68	9.34	8.17	7.26	5.39
Other Operating Expenses	5.25	0	0	0	0
Operating Expenses	26.28	17.67	13.37	9.92	7.37
Operating Income	-25.72	-15.08	-13.37	-5.82	-7.37
Interest Expense / Income	0.28	0.13	0	0	0
Other Expense / Income	-1.01	-0.3	-0.51	-0.02	-0.07
Pretax Income	-24.99	-14.9	-12.86	-5.8	-7.29
Net Income	-24.99	-14.9	-12.86	-5.8	-7.29
Preferred Dividends	0	0	0	1.27	0.49
Net Income Common	-24.99	-14.9	-12.86	-7.07	-7.78
Shares Outstanding (Basic)	36	36	19	5	4
Shares Outstanding (Diluted)	36	36	19	5	4
Shares Change	0.30%	90.84%	296.07%	10.56%	-
EPS (Basic)	-0.70	-0.42	-0.69	-1.49	-1.82
EPS (Diluted)	-0.70	-0.42	-0.69	-1.49	-1.82
Free Cash Flow	-28.72	-20.66	-11.02	-10.62	-8.23
Free Cash Flow Per Share	-0.80	-0.58	-0.59	-2.24	-1.92
Gross Margin	100.00%	100.00%	-	100.00%	-
Operating Margin	-4589.40%	-583.01%	-	-142.07%	-
Profit Margin	-4460.40%	-576.12%	-	-172.54%	-
Free Cash Flow Margin	-5124.69%	-798.85%	-	-258.99%	-
EBITDA	-23.58	-14.06	-12.29	-5.23	-6.87
EBITDA Margin	-4207.30%	-543.47%	-	-127.55%	-
Depreciation & Amortization	1.14	0.72	0.57	0.57	0.42
EBIT	-24.71	-14.77	-12.86	-5.8	-7.29
EBIT Margin	-4409.89%	-571.23%	-	-141.53%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).